On March 3, 2026, Aquestive Therapeutics, Inc. entered into an amendment to extend the Marketing Approval Deadline of a prior Purchase and Sale Agreement with RTW Investments to June 30, 2027. Additionally, the company agreed to issue a warrant to purchase 375,000 shares of its common stock at an exercise price of $4.00 per share, expiring on March 3, 2029. These agreements highlight the ongoing collaboration between Aquestive and RTW.
Company Information
Company
Aquestive Therapeutics, Inc.
Location
30 TECHNOLOGY DRIVE SOUTH
Warren, North Carolina, United States
About
Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. The company specializes in drug delivery technologies and is committed to improving patients' lives through its product pipeline. Their product candidate, Anaphylm™, aims to provide a new treatment option for severe allergic reactions. The company is headquartered in Warren, New Jersey.
WarrenBiotechnologyHealthcareHealth CareMedicalTherapeuticsPharmaceuticalBiopharma